ARTICLE | Clinical News
Subcutaneous veltuzumab regulatory update
December 8, 2014 8:00 AM UTC
FDA granted Orphan Drug designation to subcutaneous veltuzumab to treat pemphigus. The humanized anti-CD20 antibody has completed Phase II testing in non-Hodgkin’s lymphoma (NHL) and is in Phase I/II ...